Biotech Drug Report Generated Aug 20, 2026

Entresto

NVS·NOVARTIS AG

BEARISH

Drug Impact Rating3/10

Trial Phase: Approved / marketed (adult HFrEF, 2015; pediatric heart failure via Entresto Sprinkle, 2024). No pending pivotal trials
Time to Market: Already approved and marketed — adult heart-failure approval July 2015; pediatric formulation (Entresto Sprinkle) approved April 2024. US brand exclusivity has ended; the drug is now in generic-driven patent-cliff decline. No pending approvals.
Why 3/10: No hard, dated catalyst is scheduled for Entresto in the next ~12 months: the defining binary (FDA approval) passed in July 2015, US exclusivity has ended with generic entry, and the remaining sacubitril/valsartan studies in SecBot's trial data are investigator-initiated — so the share-price story is ongoing commercial erosion (already disclosed, -51% cc), not a binary event; Entresto is also one asset in a ~$285B market-cap, 30+ product portfolio, so its impact scores 3 (approved drug with no pending regulatory decision).

Actionable Insight ▼ BEARISH

Watch quarterly Entresto sales in Novartis earnings: Q2 2026 showed -51% constant-currency decline from US generics, and the question is how fast the erosion flattens and how much generic share stabilizes. Note that this is a well-known, largely priced-in headwind offset by growth in Kisqali, Kesimpta, Scemblix and Pluvicto; short interest is low (~0.27% of estimated shares outstanding, 2.7 days to cover per the latest FINRA settlement), so there is no squeeze dynamic here.

Price Chart

Loading chart...

Executive Summary

Entresto (sacubitril/valsartan) is Novartis's blockbuster heart-failure drug, approved by the FDA in July 2015 and expanded to a pediatric sprinkle form in April 2024 — but its US patent protection has now ended and generics are crushing the brand. Novartis's Q2 2026 results (SEC 6-K, July 2026) reported Entresto sales down ~51% in constant currency on US generic competition, a disclosed headwind the company is offsetting with other growth products. With no pending approval decision or pivotal readout for Entresto, the investment read is a steady, known decline rather than a binary catalyst — modest for a diversified ~$285B company.

How It Works

Entresto is a two-drug pill for heart failure. One component (sacubitril) stops an enzyme called neprilysin from breaking down the body's own heart-protective peptides, and the other (valsartan) blocks angiotensin-II receptors that would otherwise constrict blood vessels and strain the heart. Together they lower the workload on a failing heart; the FDA classifies the combination as an angiotensin II receptor blocker/antagonist (ARB) mechanism.

Trial Status

The pivotal studies are long done (approval catalysts recorded 2015-07-07 for Entresto and 2024-04-12 for Entresto Sprinkle). Remaining sacubitril/valsartan activity in SecBot's trial pipeline is investigator-initiated or competitor-run (e.g., a Phase 3 in acute decompensated heart failure with renal dysfunction; a Phase 2 in hemodialysis patients), and Novartis's own XXB750 heart-failure Phase 2 program that used sacubitril/valsartan as a comparator was terminated. A July 2026 FDA safety-labeling update added a boxed warning on fetal toxicity.

The Two-Sided Case

▲ Bull Case4

Still a standard-of-care heart-failure medicine: FDA approval catalysts are recorded for 2015-07-07 (Entresto) and 2024-04-12 (Entresto Sprinkle), and the drug remains marketed globally with a pediatric formulation.

The downside is largely disclosed and visible: Q2 2026 6-K explicitly quantifies Entresto at -51% cc on US generics, and Novartis is simultaneously growing Kisqali (+43% cc), Kesimpta (+32% cc), Scemblix (+89% cc) and Pluvicto (+43% cc), limiting stock-level damage.

Investor positioning on the ADR is not crowded bearish: FINRA short interest was ~5.24M shares (~0.27% of estimated shares outstanding, ~2.69 days to cover) as of the 2026-07-31 settlement.

Analyst consensus is roughly neutral-to-hold (10 buy / 14 hold / 4 sell / 6 strong buy) with a mean price target of $157.15 vs. a $156.24 price — i.e., no expectation of a large Entresto-driven re-rating either way.

▼ Bear Case4

US generic entry has ended the growth story: Q2 2026 results show Entresto sales down -51% in constant currency year-over-year, and the filing's risk list flags 'Entresto sales declining ~50% YoY due to US generics' as a major headwind to total revenue.

No upcoming hard catalyst for this drug — the approval binaries (2015, 2024) already passed and no Novartis-sponsored pivotal readout or PDUFA is scheduled for Entresto in the local data; remaining studies are investigator-initiated and Novartis's own XXB750 heart-failure program (with sacubitril/valsartan as comparator) was terminated.

July 2026 FDA safety-labeling action added a boxed warning for fetal toxicity (drugs acting on the renin-angiotensin system can cause fetal injury/death), a labeling overhang.

Broader NVS tape is mixed-to-negative: multiple tracked funds trimmed or exited in 2026-Q2 (Goldman -54.3%, Dodge & Cox near-exit -89.1%, BMO -59.5%, Point72 -62.6%), and FINRA daily short-volume flow was elevated (weighted ratio ~0.43 over 59 sessions).

Upcoming Catalysts

Quarterly earnings disclosures of Entresto's erosion trajectory (next 6-K) — the only recurring, dated Entresto-specific data points
Generic penetration / share-stabilization data in Novartis filings
Any FDA labeling or safety actions (e.g., follow-ups to the July 2026 fetal-toxicity boxed warning)
No PDUFA or pivotal readout for Entresto is scheduled in the next ~12 months per available data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 4

Hover a chip for the title

1 sec.gov2 sec.gov3 sec.gov4 sec.gov